No Data
No Data
Sage Moved to Underperform at BofA; Says Biogen's Buyout Impact Has Passed
Biogen Announces Initiation of Dosing in TRANSCEND
Express News | Biogen Inc - MorphoSys to Earn $35 Million Milestone Payment From Biogen
Express News | Biogen Inc - to Initiate Phase 3 Trials in Iga Nephropathy and Pmn in 2025
Express News | Biogen Inc - Secondary Endpoints Include Changes in Mvi Score
Express News | Biogen Inc - Primary Endpoint Is Resolution of Amr by Biopsy at 6 Months
Unlock the Full List